ACXP enrolls first patient in PATHFINDER ibezapolstat trial
Acurx Pharmaceuticals (ACXP) says the first patient has been enrolled in its PATHFINDER clinical trial of ibezapolstat in multiply-recurrent C. difficile infection.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.